Pharma Focus Asia

Covant Therapeutics Collaborates with Boehringer Ingelheim

Wednesday, March 29, 2023

Covant Therapeutics has entered into an exclusive research collaboration and worldwide licencing agreement with Boehringer Ingelheim covering Covant’s ADAR1 programme. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. ADAR1 is an exciting immuno-oncology target with significant therapeutic potential.

Under the terms of the agreement, Covant will be responsible for the discovery of ADAR1 small molecule inhibitors. This partnership with Covant’s exceptional scientific team and powerful platform, enables to bring next-generation immunotherapies to cancer patients.

The Covant-Boehringer Ingelheim collaboration seeks to create an ADAR1 inhibitor which is used in combination with other immunotherapies to increase the efficacy. To date, existing immunotherapies have revolutionised cancer treatment but only work in a minority of patients. Inhibiting ADAR1 has the potential to address this challenge by transforming “cold” tumours into “hot” tumours, which have more immune cells present in the tumour micro-environment.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024